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Abstract  Article Info 
Co-crystallisation is the process where the combination of two compound which are active 
pharmaceutical ingredient (API) compound with the co-former by the non-covalent interaction. 
This process is believed can enhance the physicochemical properties of the API including solubility, 
stability, dissolution rate, melting point and its bioavailability. Due to this, the research for the co-
crystallisation of the Ibuprofen and oxalic acid as it co-former had conducted by using the slow 
evaporation method. The analysis and characterisation of this co-crystal was conducted by using 
the optical microscope, Fourier transform infrared spectroscopy (FTIR), differential scanning 
calorimeter (DSC), and X-ray diffraction (XRD). The observation using optical microscope had 
shown that the co-crystal grew in the dendrite and rod shape. From the characterisation of the co-
crystals in FTIR, it shows the shift of peak which revealed the formation of the co-crystal structure. 
Then, the DSC showed that the melting point of co-crystals were higher than the pure ibuprofen. 
This showed that the co-crystal had higher thermodynamic stability than the pure API. The 
characterisation of the ibuprofen-oxalic acid (IBP: OA) co-crystal by using the XRD had proved 
that there is new crystallographic structure formed by comparing it with the pure compound. These 
results showed the co-crystals had formed. 
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1.0  Introduction   
Active pharmaceutical ingredient (API) is a 
substance that is active containing in the 
pharmaceutical products such as tablets. The dosage of 
API is according to their function for treatment, 
otherwise it also affect the diseases. This API is  
usually mixed with the excipients to form the 
pharmaceutical medicine as it cannot be present on its 
own because it poses low solubility and stability. 
Therefore, the enhancement of the API characteristics 
is believed can be achieved by forming the co-crystal 
that combines with the co-former. The co-former 
selection is the challenging parts in forming a co-
crystal. Its need a trial and error until the co-crystal is 
formed. The organic acid is likely to be used as 
conformer in co-crystallization process, for example, 
the oxalic acid. Oxalic acid, C2H2O4 is an organic 
compound which consists of two carboxylic acids. It is 
a strongest acid and acts as a reducing agent. It is also 
called as ethanedioic acid (Molecular weight 90.03) 
which usually presents in plants and vegetables.  
Ibuprofen is a well-known drug in nonsteroidal anti-
flammatory drug (NSAID) for relieves pain and 
chemically named as 2-(4-isobutylphenyl) propanoic 
acid (Gordon & Amin, 1984). It also used to relief the 
arthritis, fever and act as analgesic. The 
physicochemical properties of the co-crystal such as 
solubility, bioavailability, stability, melting point, and 
intrinsic dissolution are important in the development 
of the APIs. Ibuprofen has unique physicochemical 
properties as its pKa value is 4.4–5.2. It also has an 
amphiphilic characteristic that leads to a unique 
interaction with the lipid membrane and it has a 
detergent-like characteristic. By obtaining those 
characteristics, it gives many advantages to the 
ibuprofen as an active pharmaceutical ingredient (API) 
(Rainsford, 2013). Ibuprofen is classified in class II of 
the Biopharmaceutical Classification System, has high 
permeability and low solubility in water (Frederico & 
Carneiro, 2013). Currently, it had been supplied a form 
of tablets, thus, the formation of the co-crystal of the 
ibuprofen and the oxalic acid is believed can enhance 
its solubility, stability, and the dissolution rate. Based 
on research done by Walsh et al. (2003), the co-crystal 
of ibuprofen with other API which is nicotinamide had 
been discovered to enhance its solubility by the solvent 
evaporation method. 
Solvent evaporation is one of the methods used in 
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producing co-crystal. It is a type of solvent-based 
crystallisation technique. This technique uses a solvent 
to dissolve the mixture of API with conformer and then 
has to be evaporated until the co-crystal is formed 
(Mounika et al., 2015, Ali & Abolghasem, 2014). In 
the pharmaceutical co-crystals, the compound that has 
the lower solubility, then the other one will be 
precipitated out when there is difference in their 
solubility. Due to this condition, the polymorphism and 
the intermolecular interaction are also necessary to 
make the success of the co-crystal formation. This 
method requires higher volume of solvent. (Tanvee & 
Deshpande, 2014) 
The objective of this paper is to study the formation 
of ibuprofen and glutaric acid co-crystal via slow 
evaporation technique in ethanol solvent. The 
physicochemical properties of ibuprofen and glutaric 
acid co-crystal are assessed through the 
characterization of crystal product using analytical 
instruments such as optical microscopy, FTIR, DSC 
and PXR. 
2.0 Methodology  
2.1 Materials 
Ibuprofen (IBP, MW = 206.28082 g/mol) was 
purchased from Shasun Pharmaceutical Limited, India 
(Batch No.: IB 11070248) (SN Grade). Glutaric acid 
(GA, MW = 132.11642 g/mol) was purchased from 
MERCK, Germany. Ethanol (MW = 46.07 g/mol) was 
purchased from Sigma-Aldrich, Germany. All 
compounds were used without further purification.  
2.2 Preparation of ibuprofen-oxalic acid 
Slow evaporation technique was used in this work 
to produce a co-crystal (Mounika et al., 2015). Five 
molar ratios of ibuprofen to the oxalic acid used in this 
research to form the co-crystal. It was started with 0.5:1 
mole ratio where 2.292 g of the ibuprofen mixed with 
0.639 g of oxalic acid. Then, 5 ml of ethanol(solvent) 
was added to dissolve the ibuprofen and oxalic acid. 
The solution then was heated at 50 °C and increased 
until all the solute dissolved. These steps were repeated 
for four different mole ratios (1.5:1, 2.5:1, 3.5:1, and 
4.5:1) to find the most suitable mole ratio to produce 
co-crystal of ibuprofen and oxalic acid. The 
concentrations for each mole ratio were tabulated in 
Table 1. For the next experiment, the ibuprofen and 
oxalic acid were dissolved in the solvent ethanol. The 
concentrations for each molar are stated in Table 1. 
Table 1: Mass of ibuprofen and oxalic acid for each molar 
ratio in ethanol solvent. 
Molar ratio 
(IBP:OA) 
Mass of 
ibuprofen, IBP 
 (g) 
Mass of oxalic 
acid, OA 
 (g) 
0.5:1 2.929 0.639 
1.5:1 2.929 1.918 
2.5:1 2.929 3.916 
3.5:1 2.929 4.474 
4.5:1 2.929 5.753 
2.3 Optical microscopy analysis 
The sample was taken from the solution. The 
morphology of the ibuprofen-oxalic acid co-crystal 
was observed by using optical microscope (Meiji 
Techno 1599) equipped with digital camera device 
(Model: ZC 505) and Zarbecco software for live 
viewing and capturing of images of the co-crystal 
morphology on the computer screen. 
2.4 Fourier transform infra-red spectroscopy (FTIR 
analysis 
Fourier transform infra-red spectroscopy used in 
this study is of Thermo Nicolet model. This instrument 
measures the IR spectra of the sample by using the 
wavenumbers in the range of 1500 to 4000 cm−1. The 
analysis was performed to study the molecular 
interaction of the ibuprofen-oxalic acid co-crystal. 
2.5 Differential scanning calorimetric (DSC) analysis 
The harvested samples were weighed and analysed 
using the DSC 820 (Metler Toledo) insturment. Eight 
milligram of co-crystal formed was heated at heating 
rate of 10 °C/min. The nitrogen gas was used as the 
supply gas, and the process was heated from 0−400 °C. 
The results of the measurement was recorded. 
2.6 2.6 X-ray powder diffraction (XRPD) analysis 
The sample was dried in an oven at 40 °C and being 
crushed using portal and mortar to get the co-crystal in 
powder form. The sample of co-crystal formed was 
analysed using the powder diffractometer (Rigaku) 
with Cu Kα, tube voltage of 40 kV, current of 40 mA. 
Then, the sample was placed on a thin glass and the 
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patterns were being examined from 3° to 40° at 2θ 
values with the steps size 0.01° per minute. 
3.0 Results and discussion 
3.1 Co-crystal of ibuprofen-oxalic acid morphology 
The crystals grew like a thin rod shape in the molar 
ratio of 0.5:1 and started to formed dendrite shape in 
1.5:1 ratio with more branches as shown in Table 2. It 
was observed that for the 2.5:1 and above, the 
observations were not so clear as the crystal had broken 
during the preparation for the slide. There were fewer 
solutions left in the vials which most of them were 
converted into crystal form. The crystal form in the 
2.5:1 seems like thin rod shape. The same shape was 
formed in the 3.5:1 sample. The 4.5:1 has shown the 
crystals like leave plate shape and the large crystal 
form is a rod shape. From these results, it proved that 
the co-crystal of ibuprofen and oxalic had formed 
because of the change in the structure and shape from 
the pure component. 
3.1 Characterisation results of Ibuprofen-oxalic acid 
co-crystal 
Fig. 1 shows the result from the FTIR analysis. The 
analysis had been performed for the pure ibuprofen, 
pure oxalic acid and co-crystal in 0.5:1, 1.5:1, 2.5:1, 
3.5:1, and 4.5:1. The FTIR spectrum for the ibuprofen 
revealed peaks at 1506.96 cm−1 which was assigned as 
aromatic ring C=C⎼C, 1700.77 cm−1 as carboxylic 
acid, 2867.90 cm−1, and 2954.19 cm−1 as methyl C⎼H. 
While for the oxalic acid, the peaks revealed at 3412.46 
cm−1 and 1668.44 cm−1 represent as the hydroxy group 
OH and C=C, respectively.  
The shift of peaks can be seen in the co-crystal 0.5:1 
molar ratio as the peaks that can assigned as carboxylic 
acid is at 1706.46 cm−1, 2.5:1 molar ratio at 1702.29 
cm−1, 3.5:1 molar ratio at 1704.51 cm−1, and 1704.98 
cm−1.The new peak for the molar ratio 4.5:1 appears at 
1730.95 cm−1 which can be assigned as ester or 
aldehyde functional group. However, for the ratio 1.5:1 
co-crystal, the peaks of oxalic acid at 1668.44 cm−1 had 
shifted to 1677.42 cm−1. 
Table 2: Morphology of co-crystal of ibuprofen-oxalic acids using optical microscopy. 
Molar ratio 
(IBP:OA) 
4X magnification 10X magnification 20X magnification 
0.5:1 
   
1.5:1 
   
2.5:1 
   
3.5:1 
   
4.5:1 
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Temperature, C 
 
Fig.1: FTIR results for the pure IBP(a); co-crystal of 
0.5:1(b), 1.5:1(c), 2.5:1(d), 3.5:1(e), 4.5:1(f) molar ratio, 
and pure oxalic acid(g). 
 
These peaks are assigned as the C=C. The new peak 
at 1610.20 cm−1 presented in the molar ratio 1.5:1 
which can be indicated as aromatic ring. Another peak 
was formed for the oxalic acid, which can be 
characterised as hydroxy group, OH which is at 
3412.46 cm−1. This peak had shifted to 3420.79 cm−1, 
3414.29 cm−1, 3413.12 cm−1, 3414.79 cm−1, and 
3417.79 cm−1 at molar ratio 0.5:1, 1.5:1, 2.5:1, 3.5:1, 
and 4.5:1, respectively. 
The IR spectra peaks for co-crystals, ibuprofen and 
oxalic acid were summarised in Table 4. Fig. 2 
represents the curves for the co-crystal of the 0.5, 1.5, 
2.5, 3.5, 4.5 oxalic acid and pure ibuprofen. The peaks 
of 0.5:1, 1.5:1, 2.5:1, 3.5:1, and 4.5:1 co-crystals show 
at temperature of 101.04 °C, 101.34 °C, 101.04 °C, 
101.53 °C, and 101.34 °C, respectively. While the pure 
ibuprofen shows a melting point peak at 80.72 °C 
which are endothermic signal. These showing that the 
co-crystals have higher thermodynamic stability than 
the API which is ibuprofen itself. The higher energy 
was needed by the co-crystals to break the crystal 
lattice. Some research had presented the value of peaks 
appear for the oxalic acid from the characterisation of 
the DSC was at 195.38 °C, which is higher than the co-
crystal melting point (Oana et al., 2012). These can be 
proven that the co-crystal had formed in the molar ratio 
of 0.5:1, 1.5:1, 2.5:1, 3.5:1, and 4.5:1.  
 
Fig. 2: DSC curves of the pure IBP (a), co-crystal of 
0.5:1(b), 1.5:1(c), 2.5:1(d), 3.5:1(e), and 4.5:1(f) molar 
ratio. 
 
Fig. 3: XRD results for the pure oxalic acid(a), pure 
IBP(b), co-crystal of 4.5:1(c), 3.5:1(d), 2.5:1(e), 1.5:1(f), 
and 0.5:1(g) molar ratio. 
However, there are also another small peak appear 
after that. The instability of the co-crystal structure had 
observed due to the formation of another peak in the all 
those co-crystals. These peaks indicate that there is 
instability is form in that temperature. For example, 
ibuprofen showing one more peak at temperature  
307.6 °C, therefore, the crystallinity of the ibuprofen 
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was broken in that temperature. The peaks can be 
summarised in the  Table 3.  
While in Fig. 3, it presents the diffractogram of the 
co-crystals and it pure compounds which were 
ibuprofen and oxalic acid. The diffractogram of the 
ibuprofen can be observed the peaks at 2θ: 12.26, 
24.54 and 37.66. Meanwhile peak observed for 
oxalic acid are 14.80, 18.66, 25.72, and both pure 
compounds show a good agreement with the value 
published in the literature (Jang et al., 2017). 
 
Table 3: The temperature of other peaks formed at each co-
crystals and pure ibuprofen. 
Molar ratio Temperature (C) 
0.5:1 71.64, 178.90, 304.66 
1.5:1 135.09, 189.83 
2.5:1 75.20, 136.28 
3.5:1 156.93, 290.77 
4.5:1 65.27, 182.45, 294.76 
Ibuprofen 307.6 
Table 4: IR spectra peaks for co-crystals, ibuprofen and oxalic acid. 
 
4.0 Conclusion  
The co-crystal of the ibuprofen and oxalic acid via 
evaporation method had formed the co-crystals. The 
observation of the co-crystal under the optical 
microscope gave the results of dendrite shape of the co-
crystals. While the FTIR result for co-crystal had 
shown the shift of peaks. The DSC results showed that 
the co-crystal had higher stability than the ibuprofen. 
The XRD diffractogram results presented that there 
was new crystallographic structure which proved that 
those were co-crystal formed. This proved that the co-
crystal formation can improved the physicochemical 
properties of the API. 
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